this survey as amended by FDA's February 25 faxes and contingent
upon FDA re-submitting for approval the full set of prescription
and OTC drug label information sheets before fielding this survey.
In particular, FDA agreed to make the label information sheets
consistent with the most current OTC label formats and to not
provide financial incentives to respondents. Finally, FDA agreed
that the mall-intercept sampling methodology used in this survey
will not permit the results to be generalizable to the U.S.
Inventory as of this Action
The purpose of this study is to
examine gender differences in risk/benefit perception for a
hypothetical Rx and OTC drug.